- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
HVO
LSE
Week ended 07 Aug 2026
Weekly Investor Report
hVIVO plc · Healthcare · Diagnostics & Research
Latest close
0.07 GBP
-6.8%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -7.9% below the Trend Line and sits at 37.4% of its 52-week range. The latest completed week returned -6.8%, after a 0.7% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers. The latest news-sentiment score is 50/100.
Setup score
26
out of 100
Latest Close
0.07 GBP
7 Aug 2026
1W Return
-6.8%
latest completed week
4W Return
0.7%
short-term follow-through
12W Return
-8.0%
quarterly tape
Trend Breadth
25.0%
13 of 52 weeks active
Volume Ratio
1.0x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-6.8%
Latest completed week; four-week move 0.7%.
Indicator stack
14/32
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 35.69%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
5 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -7.9% below the Trend Line and sits at 37.4% of its 52-week range. The latest completed week returned -6.8%, after a 0.7% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.3912-week average 0.37
12-week confirmation
Trend active7/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.39Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 0.7% over four weeks, -8.0% over 12 weeks, and -36.4% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year13
Trend breadth25.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.65Latest activity-pressure read.
Pressure change-79.6%Four-week change in activity pressure.
Leadership-15.03Latest relative-leadership reading.
RS change8.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 76%
Model confidence 60%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength6/100Blend of value, momentum, and quality. Underlying universe rank 95; rank 1 is best.
Value19/100Relative valuation strength. Underlying universe rank 82; rank 1 is best.
Quality21/100Profitability and accounting quality. Underlying universe rank 80; rank 1 is best.
Momentum21/100Medium-term price momentum. Underlying universe rank 80; rank 1 is best.
Growth21/100Revenue and earnings growth. Underlying universe rank 80; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- - Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- -6.9% Operating profit retained from revenue.
- Free-cash-flow margin
- -33.9% Free cash flow generated from revenue.
- Return on invested capital
- -6.3% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -25.4% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -301.2% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 0/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- - Net share repurchases relative to market value.
- Shareholder yield
- - Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 5 relevant articles.
0 positive · 5 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-38.7%Distance below the 52-week high.
13-week volatility6.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher10 of 2616 weeks finished lower.
Best week+39.3%Week of 13 Feb.
Worst week-20.9%Week of 24 Apr.
Latest week-6.8%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains2
Flat weeks0
Modest losses6
Sharp losses10
Recent vol6.5%13-week weekly-return volatility.
Base vol11.5%52-week weekly-return volatility.
Up/down split17/34Count of positive and negative weeks in the 52-week window.
Average skew11.2% / -6.0%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorGB Healthcare
4-week rank36 / 79
Group average0.0%
Trend breadth27.8%
Trend27.8%active weekly trend signals
MD44.3%positive activity pressure
RS22.8%positive relative leadership
Four-week leaders
IndustryGB Diagnostics & Research
4-week rank5 / 10
Group average-2.7%
Trend breadth30.0%
Trend30.0%active weekly trend signals
MD20.0%positive activity pressure
RS20.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape23/100
Trend, activity pressure, participation, and risk combine to a 23/100 tape read.
Indicator analysis42/100Latest 12-week confirmation: trend 7/12, activity pressure 6/12, relative leadership 1/12.
Activity pressure 0.39; No reversal markers Next-Week ExpectancyNegative 35.69%Next-week expectancy is negative with a 35.69% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors15/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 50 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 5 relevant articles.
REG - hVIVO PLC - H1 2026 Trading Update Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 0.07 GBP | -6.8% | 0.07 GBP | 0.17 GBP | -0.65 | -15.03 | 5.6M | Off |
| 31 Jul 2026 | 0.07 GBP | -1.3% | 0.07 GBP | 0.17 GBP | -0.66 | -9.89 | 6.1M | Off |
| 24 Jul 2026 | 0.07 GBP | 11.9% | 0.07 GBP | 0.17 GBP | -0.65 | -8.54 | 9.5M | Off |
| 17 Jul 2026 | 0.07 GBP | -2.2% | 0.07 GBP | 0.17 GBP | -0.59 | -18.07 | 4.0M | Off |
| 10 Jul 2026 | 0.07 GBP | -4.2% | 0.07 GBP | 0.17 GBP | -0.36 | -16.44 | 2.4M | Off |
| 3 Jul 2026 | 0.07 GBP | 3.6% | 0.07 GBP | 0.17 GBP | -0.16 | -15.24 | 467.8K | On |
| 26 Jun 2026 | 0.07 GBP | -12.1% | 0.07 GBP | 0.17 GBP | 0.07 | -17.97 | 1.0M | On |
| 19 Jun 2026 | 0.08 GBP | -7.1% | 0.07 GBP | 0.17 GBP | 0.16 | -6.70 | 981.0K | On |
| 12 Jun 2026 | 0.08 GBP | -4.5% | 0.07 GBP | 0.17 GBP | 0.18 | -1.56 | 584.9K | On |
| 5 Jun 2026 | 0.09 GBP | 6.6% | 0.07 GBP | 0.17 GBP | 0.13 | 3.08 | 14.5M | On |
| 29 May 2026 | 0.08 GBP | 2.5% | 0.07 GBP | 0.17 GBP | 0.05 | -4.58 | 5.1M | On |
| 22 May 2026 | 0.08 GBP | 8.0% | 0.07 GBP | 0.18 GBP | 0.15 | -7.79 | 12.9M | On |
| 15 May 2026 | 0.07 GBP | -1.3% | 0.07 GBP | 0.18 GBP | 0.41 | -14.66 | 11.2M | On |
| 8 May 2026 | 0.08 GBP | 4.1% | 0.07 GBP | 0.18 GBP | 0.78 | -16.33 | 12.9M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.